AstraZeneca is one of Austria’s leading research-based pharmaceutical companies
Research drives us and delivers significant value to society. By 2030, we aim to make at least 20 new medicines available to patients. We are also pursuing this goal intensively through clinical trials in Austria.
With around 180 new molecules currently under investigation, our development pipeline is one of the leading pipelines in the pharmaceutical industry.1
Top-10 companies for ongoing clinical studies in Austria2
2026
Top 15 pharmaceutical companies for revenues in hospital + retail market in Austria3
(€ mill.), 2025
Ranking of the top-15 pharmaceutical companies with the most ongoing clinical trials in Austria2
(number), 2026
Leader in clinical trials in oncology
Top-5 companies for ongoing lung cancer clinical studies in Austria
(number), 2025
Top-5 companies for ongoing breast cancer clinical studies in Austria
(number), 2026
We are particularly proud that we are able to cover a broad therapeutic spectrum with our clinical trials in Austria: as such, we have active studies in all four of AstraZeneca’s therapeutic areas – Oncology, CVRM, RIV, and Rare Disease (through our subsidiary Alexion).
Clinical studies
by therapeutic area
Every Euro invested in clinical trials by the pharmaceutical industry generates €1.97 for the Austrian economy.
The performance of clinical trials by the pharmaceutical industry leads – in addition to the benefit for patients – to positive macroeconomic effects.
AstraZeneca’s investment in clinical trials translates into benefits for the healthcare system in terms of financial savings, targeting and improving treatment as well as the access to new drugs.
Every Euro invested in clinical trials by the pharmaceutical industry generates €1.97 for the Austrian economy.
The performance of clinical trials by the pharmaceutical industry leads – in addition to the benefit for patients – to positive macroeconomic effects.
Thanks to this leverage effect, the €7.2 million invested in 2025 translates into €14.2 million of expected benefits for the Austrian healthcare system.
Clinical trials bring benefits for patients, the healthcare system, research, and the economy
Sources:
- https://www.astrazeneca.com/our-therapy-areas/pipeline.html, as of 27 July 2026, last accessed on 19 August 2026
- List of all active studies with a start date between January 2022 and March 2026 (source: Trialtrove, as of March 2026)
- IQVIA
- Tracking economic change over a decade: an analysis of Austria’s industry-sponsored clinical trial landscape and implications for policy, Walter et. al, available at https://doi.org/10.1080/13696998.2026.2678777